Tamir Rashid is a Reader and Consultant Hepatologist at Imperial College London (ICL). As a Wellcome Trust Clinical PhD Fellow (Cambridge), he generated the world's first iPS hepatocyte disease models and established proof of principle for their therapeutic use. He was then awarded an MRC Clinician Scientist Fellowship to advance this technology using genetic and biomaterial engineering (Stanford, USA) before returning to the UK to start his own lab, where his focus has been in translating these advances towards clinical application.
Over the last ten years, the significance of Dr Rashid’s work has been recognised through the receipt of numerous international (the American Liver Association Fellow’s Prize) and national (Academy of Medical Sciences UK Young Investigator & British Liver Association Young Investigator) prizes.
The Liver Regeneration Group (LRG), led by Dr Rashid, leverages state-of-the-art induced pluripotent stem cell (iPSC) technology to improve understanding of liver physiology and disease. Using iPSCs derived from patients and combining this with bioengineering and gene editing, the group generate cell, organoid and animal models and apply this toward the creation of novel therapies. Finally, to better understand which patients are most likely to benefit from such advanced therapeutics, the team uses disease registries and electronic health records to precisely characterise disease natural history. The LRG is located on the Hammersmith Campus (Commonwealth Building, 10th floor).
et al., 2023, RGD density along with substrate stiffness regulate hPSC hepatocyte functionality through YAP signalling, Biomaterials, Vol:293, ISSN:0142-9612, Pages:1-17
et al., 2022, Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice, Nature Metabolism, Vol:4, ISSN:2522-5812, Pages:1812-1829
et al., 2022, Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency, Jhep Reports, Vol:4
et al., 2022, Dysregulated RNA polyadenylation contributes to metabolic impairment in non-alcoholic fatty liver disease, Nucleic Acids Research, Vol:50, ISSN:0305-1048, Pages:3379-3393
et al., 2022, Sulfated Alginate Reduces Pericapsular Fibrotic Overgrowth on Encapsulated cGMP-Compliant hPSC-Hepatocytes in Mice, Frontiers in Bioengineering and Biotechnology, Vol:9, ISSN:2296-4185